408 related articles for article (PubMed ID: 30341016)
1. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
[No Abstract] [Full Text] [Related]
2. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
4. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
[No Abstract] [Full Text] [Related]
6. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
7. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.
Xu Y; Fan Y
Cancer Biol Ther; 2019; 20(2):145-149. PubMed ID: 30422759
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
[No Abstract] [Full Text] [Related]
10. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
11. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
12. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
13. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
Rotow JK; Woodard GA; Urisman A; McCoach CE; Bivona TG; Elicker BM; Jablons DM; Blakely CM
Clin Lung Cancer; 2019 Mar; 20(2):e137-e141. PubMed ID: 30553716
[No Abstract] [Full Text] [Related]
14. Acquired Resistance to Crizotinib in NSCLC with METÂ Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
15. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
[No Abstract] [Full Text] [Related]
16. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
17. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
Ding G; Wang J; Ding P; Wen Y; Yang L
Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
[TBL] [Abstract][Full Text] [Related]
18. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
van Kempen LC; Wang H; Aguirre ML; Spatz A; Kasymjanova G; Vilacha JF; Groves MR; Agulnik J; Small D
J Thorac Oncol; 2018 Sep; 13(9):e161-e163. PubMed ID: 29704676
[No Abstract] [Full Text] [Related]
19. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
20. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
Iwama E; Sakai K; Azuma K; Harada D; Nosaki K; Hotta K; Nishio M; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Cancer Sci; 2018 Dec; 109(12):3921-3933. PubMed ID: 30289575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]